Email Medtest DX Medtest Headquarters Medtest Facebook Medtest Linkedin

Tricyclics Antidepressants



DRI Urine Drug Screening


Format: Liquid
Wavelength: 340 nm
Linearity: 1000 ng/mL
Storage Temperature: 2 - 8° C
  • Description
  • Ordering Information
  • Related Products
  • Documentation

Intended Use

The DRI® Tricyclics Serum Tox Assay is intended for the qualitative and semiquantitative determination of tricyclic antidepressants in human serum, plasma or urine.


The DRI Tricyclics Serum Tox Assay is a homogeneous enzyme immunoassay using ready to-use liquid reagents. Specific tricyclic antibodies were used to detect most tricyclic antidepressants in serum, plasma, or urine. The test is based on the competition of an enzyme, glucose-6-phosphate dehydrogenase (G6PDH), labeled-drug and the drug from the sample for a fixed amount of specific antibody binding sites. In the absence of the drug from the sample, the specific antibody binds the enzyme-labeled drug and the enzyme activity is inhibited. This phenomenon creates a direct relationship between drug concentration in the sample and the enzyme activity. The enzyme activity is determined spectrophotometrically at 340 nm by measuring its ability to convert nicotinamide adenine dinucleotide (NAD) to NADH.